Published in Eur J Clin Pharmacol on November 17, 2005
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci (2013) 0.91
Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology (2008) 0.90
Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci (2008) 0.84
The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. Eur J Clin Pharmacol (2007) 0.83
First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. Biochem Pharmacol (2013) 0.83
Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna) (2014) 0.80
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br J Clin Pharmacol (2014) 0.79
Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J (2015) 0.76
Effect of Garden Cress Seeds Powder and Its Alcoholic Extract on the Metabolic Activity of CYP2D6 and CYP3A4. Evid Based Complement Alternat Med (2014) 0.76
Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin. Saudi Pharm J (2014) 0.75
Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J (1987) 5.31
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med (2003) 3.37
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 2.17
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther (2000) 1.60
The misuse of urinary metabolite excretion data in drug metabolism studies. Pharmacogenetics (1993) 1.39
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics (1994) 1.25
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther (2000) 1.24
Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol (1987) 1.17
Dextromethorphan. An overview of safety issues. Drug Saf (1992) 1.10
Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther (1999) 1.05
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics (1993) 1.04
Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg (1996) 1.03
N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex. Int J Clin Pharmacol Ther Toxicol (1990) 1.02
Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica (1986) 1.00
Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem (2003) 1.00
Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res (1999) 0.99
Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther (2003) 0.98
Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol (1997) 0.96
The role of dextromethorphan in pain control. Can J Anaesth (2000) 0.93
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol (2001) 0.92
Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics (2000) 0.91
Dextromethorphan-induced psychosis. Am J Psychiatry (2000) 0.90
Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol (1999) 0.90
Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl (1996) 0.90
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol (2004) 0.88
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics (1998) 0.87
Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr (1985) 0.85
Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther (1992) 0.85
The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci (2002) 0.84
Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther (2003) 0.84
Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl (1996) 0.83
Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther (2001) 0.81
A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy (1999) 0.81
Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther (2002) 0.81
Phenotypic differences in dextromethorphan metabolism. Pharm Res (1989) 0.80
Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther (2004) 0.80
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther (1999) 0.80
[A new, rapid and robust genotyping method for CYP2C9 and MDR1]. Ann Biol Clin (Paris) (2003) 0.80
High-affinity dextromethorphan and (+)-3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J Pharmacol Exp Ther (1992) 0.80
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol (2001) 0.78
Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol (1999) 0.78
Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther (1996) 0.78
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol (1988) 0.78
The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett (2001) 0.77
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther (1999) 0.77
Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos (2000) 0.76
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther (1999) 0.75
Dextromethorphan O-demethylation polymorphism in an African-American population. Eur J Clin Pharmacol (1999) 0.75
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics (1999) 0.75
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Estimating the impact of school closure on influenza transmission from Sentinel data. Nature (2008) 7.98
Risk factors of influenza transmission in households. Br J Gen Pract (2004) 5.25
Comparison of routine and on-demand prescription of chest radiographs in mechanically ventilated adults: a multicentre, cluster-randomised, two-period crossover study. Lancet (2009) 3.33
Epidemiology and treatment of painful procedures in neonates in intensive care units. JAMA (2008) 3.19
Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med (2009) 2.70
Influenza epidemics in the United States, France, and Australia, 1972-1997. Emerg Infect Dis (2004) 2.37
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
Estimating in real time the efficacy of measures to control emerging communicable diseases. Am J Epidemiol (2006) 1.94
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
Prediction of the spread of influenza epidemics by the method of analogues. Am J Epidemiol (2003) 1.85
Association of influenza epidemics with global climate variability. Eur J Epidemiol (2004) 1.64
Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology (2007) 1.58
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther (2002) 1.57
Prediction of evolution toward brain death upon admission to ICU in comatose patients with spontaneous intracerebral hemorrhage using simple signs. Transpl Int (2013) 1.48
Premedication for neonatal endotracheal intubation: results from the epidemiology of procedural pain in neonates study. Pediatr Crit Care Med (2013) 1.47
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol (2011) 1.42
Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr (2006) 1.42
Potential for a global dynamic of Influenza A (H1N1). BMC Infect Dis (2009) 1.42
Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation. Transplantation (2008) 1.41
[Pressure sores in a university hospital]. Presse Med (2006) 1.40
Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther (2006) 1.37
Online detection and quantification of epidemics. BMC Med Inform Decis Mak (2007) 1.33
Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study. PLoS One (2009) 1.29
Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet (2012) 1.26
S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools. BMC Infect Dis (2006) 1.23
Transmissibility and geographic spread of the 1889 influenza pandemic. Proc Natl Acad Sci U S A (2010) 1.22
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother (2010) 1.19
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol (2010) 1.15
Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol (2003) 1.14
Predicted long-term outcome of corneal transplantation. Ophthalmology (2009) 1.13
Physiological diurnal variability and characteristics of the ocular pulse amplitude (OPA) with the dynamic contour tonometer (DCT-Pascal). Int Ophthalmol (2007) 1.10
Different transmission patterns in the early stages of the influenza A(H1N1)v pandemic: a comparative analysis of 12 European countries. Epidemics (2011) 1.10
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09
Temporal variability and social heterogeneity in disease transmission: the case of SARS in Hong Kong. PLoS Comput Biol (2009) 1.09
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget (2010) 1.09
The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. Arthritis Rheum (2009) 1.05
Does the effectiveness of control measures depend on the influenza pandemic profile? PLoS One (2008) 1.05
Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.05
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics (2012) 1.04
Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol (2008) 1.03
Contribution of mathematical modeling to the fight against bacterial antibiotic resistance. Curr Opin Infect Dis (2011) 1.01
Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol (2003) 0.98
Thyroid-stimulating hormone, 5-HTTLPR genotype, and antidepressant response in depressed women. Psychiatr Genet (2011) 0.98
The R0 package: a toolbox to estimate reproduction numbers for epidemic outbreaks. BMC Med Inform Decis Mak (2012) 0.98
Improving general practice based epidemiologic surveillance using desktop clients: the French Sentinel Network experience. Stud Health Technol Inform (2010) 0.97
Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol (2006) 0.97
Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol (2006) 0.96
Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. BMC Public Health (2012) 0.96
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis (2013) 0.95
Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. Eur J Gastroenterol Hepatol (2012) 0.93
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics (2014) 0.93
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol (2007) 0.93
Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer (2006) 0.92
Access to general practitioner services: the disabled elderly lag behind in underserved areas. Eur J Public Health (2005) 0.92
Atazanavir urinary stones in an HIV-infected patient. AIDS (2006) 0.91
Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis (2014) 0.91
Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther (2003) 0.90
Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics (2004) 0.90
High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother (2003) 0.90
Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population. PLoS One (2013) 0.90
A method for selecting and monitoring medication sales for surveillance of gastroenteritis. Pharmacoepidemiol Drug Saf (2010) 0.89
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros (2011) 0.88
Origin of the prevalent SFTPB indel g.1549C > GAA (121ins2) mutation causing surfactant protein B (SP-B) deficiency. Am J Med Genet A (2006) 0.87
Association between ABO blood group and fibrosis severity in chronic hepatitis C infection. Dig Dis Sci (2006) 0.87
Determination of French influenza outbreaks periods between 1985 and 2011 through a web-based Delphi method. BMC Med Inform Decis Mak (2013) 0.87
The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol (2009) 0.87
Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab (2008) 0.87
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett (2006) 0.87
Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom (2010) 0.86
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer. Mod Pathol (2005) 0.86
Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology (2010) 0.86
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology (2004) 0.86
Intrinsic epidemicity of Streptococcus pneumoniae depends on strain serotype and antibiotic susceptibility pattern. Antimicrob Agents Chemother (2011) 0.86
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS (2005) 0.85
Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS (2009) 0.85
Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol (2009) 0.85
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol (2003) 0.84
A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet (2012) 0.83
Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides. PLoS One (2008) 0.83
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br J Clin Pharmacol (2006) 0.83
Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr (2011) 0.83
Imprint cytology in tumor tissue bank quality control: an efficient method to evaluate tumor necrosis and to detect samples without tumor cells. Virchows Arch (2010) 0.83
Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. AIDS (2010) 0.82